PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The phosphatidylinositol 3-kinase (PI3K) pathway is crucial for cell growth and survival, frequently dysregulated in cancer.
• Abnormal PI3K activation, particularly via PIK3CA mutations, is a key driver in breast cancer, especially the HER2-positive subtype.
• PIK3CA mutations confer resistance to HER2-targeted therapies, posing a significant clinical challenge.

Purpose of the Study:

• To review current PI3K inhibitors and their potential therapeutic role in HER2-positive breast cancer.
• To provide an overview of ongoing clinical trials investigating PI3K inhibitors in this patient population.
• To discuss PIK3CA mutational testing and identify knowledge gaps for effective PI3K inhibitor application.

Main Methods:

• Literature review of PI3K pathway signaling in breast cancer.
• Analysis of PIK3CA mutation prevalence and its impact on HER2-targeted therapy resistance.
• Survey of available PI3K inhibitors and ongoing clinical trials.
• Review of PIK3CA mutational testing methodologies and challenges.

Main Results:

• PIK3CA mutations are found in ~30% of early-stage HER2+ breast cancers, contributing to therapeutic resistance.
• Several PI3K inhibitors are in development or clinical trials for HER2+ breast cancer.
• PIK3CA mutational testing is becoming increasingly important for patient stratification.
• Knowledge gaps exist regarding optimal use of PI3K inhibitors and resistance mechanisms.

Conclusions:

• Targeting the PI3K pathway with inhibitors represents a promising strategy for HER2-positive breast cancer, particularly in cases with PIK3CA mutations.
• Effective implementation requires robust PIK3CA mutational testing and further research into resistance mechanisms.
• Ongoing clinical trials will clarify the role of PI3K inhibitors in combination with HER2-targeted agents.